Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial

American Journal of Clinical Dermatology

Volumn 12, Issue 1, 2011, Pages 51-62

  Kimball, Alexa B ^a   Bensimon, Arielle G ^b   Guerin, Annie ^b   Yu, Andrew P ^b   Wu, Eric Q ^b   Okun, Martin M ^c   Bao, Yanjun ^c   Gupta, Shiraz R ^c   Mulani, Parvez M ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ANALYSIS GROUP   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab, adverse reactions; Adalimumab, therapeutic use; Anti TNF monoclonal antibodies, therapeutic use; Arthritis; Cardiovascular disorders; Depression; Diabetes mellitus; Hyperlipidaemia; Hypertension; Obesity; Productivity costs; Psoriasis, treatment; Psoriatic arthritis; Quality of life

Indexed keywords

ADALIMUMAB; PLACEBO;

ADL DISABILITY; ADULT; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SHORT FORM 36; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COMORBIDITY; DOUBLE-BLIND METHOD; EFFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78649676145     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11530640-000000000-00000     Document Type: Article

References (25)

1. Adams PF, Hendershot GE, Marano MA; Centers for Disease Control and Prevention/National Center for Health Statistics. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 1999 Oct; 10 (200): 1-203
2. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6 (6): 383-92
3. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 Sep; 41 (3 Pt 1): 401-7
4. Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006; 17 (1): 24-8
5. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008 Nov; 59 (5): 772-80
6. Kimball AB, Gladman D, Gelfand JM, et al.; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008 Jun; 58 (6): 1031-42
7. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008; 19 (1): 5-21
8. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008 Apr; 7 (4): 373-7
9. Sterry W, Strober BE, Menter A; International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007 Oct; 157 (4): 649-55
10. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arth-ritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978 Aug; 53 (8): 511-8
11. Gelfand JM, Gladman DD, Mease PJ, etal. Epidemiology ofpsoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005 Oct; 53 (4): 573-7
12. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005 Mar;64 Suppl. 2: ii14-7
13. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008 Sep; 159 (3): 704-10
14. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006; 212 (2): 123-7
15. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215 (1): 17-27
16. Schmitt J, Ford DE. Understanding the relationship between objective dis-ease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis: a structural equations modeling approach. Gen Hosp Psychiatry 2007 Mar-Apr; 29 (2): 134-40
17. Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: a study in1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008 Nov; 159 (5): 1116-23
18. Saurat JH, Stingl G, Dubertret L, et al.; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 Mar; 158 (3): 558-66
19. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Der-matol 2008 Jan; 58 (1): 106-15
20. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008 Mar; 158 (3): 549-57
21. Revicki DA, Willian MK, Menter A,et al. Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007; 18 (6): 341-50
22. Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006 Sep; 4: 71-82
23. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993 Nov; 4 (5): 353-65
24. Chao EL, Hall K. National compensation survey: occupational earnings in the United States, 2007 [online]. Available from URL: http://www.bls.gov/ncs/ ncswage2007.htm#Wage-Tables [Accessed 2008 Nov 11] 25.
25. Richards HL, Fortune DG, Weidmann A, et al. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 2004 Dec; 151 (6): 1227-33